Medtronic's Stock Plummets 4.15% Amid Massive Recall of Insulin Pumps, Trading Volume Ranks 52nd

On May 22, 2025, Medtronic's trading volume reached 11.94 billion, ranking 52nd in the day's stock market. Medtronic (MDT) fell 4.15%, marking three consecutive days of decline, with a total drop of 6.97% over the past three days.

Medtronic has announced a significant recall of its MiniMed 600 series insulin pumps due to potential malfunctions that could lead to over-delivery or under-delivery of insulin. This recall affects approximately 300,000 devices worldwide, raising concerns about patient safety and the company's ability to manage the crisis effectively.

In response to the recall, Medtronic has established a dedicated support team to assist patients and healthcare providers. The company is also working closely with regulatory authorities to address the issue and ensure the safety of its products. However, the recall has raised questions about the reliability of Medtronic's insulin pumps and the potential impact on the company's reputation and market share.

Medtronic's stock price has been under pressure due to the recall, with investors expressing concerns about the financial implications and the potential for further regulatory scrutiny. The company's management has assured investors that it is taking all necessary steps to resolve the issue and minimize the impact on its business. However, the recall has highlighted the challenges faced by Medtronic in maintaining the quality and safety of its products in a competitive market.